Rituximab to Treat Severe Hemophilia A

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

November 30, 2010

Study Completion Date

January 31, 2012

Conditions
Hemophilia A
Interventions
DRUG

Rituximab

Rituximab by slow intravenous infusion; for participants greater than or equal to 10 kg, 375 mg per m\^2 BSA weekly for 4 weeks; for participants less than 10 kg, 12.5 mg/kg weekly for 4 weeks

Trial Locations (13)

15213

Hemophilia Center of Western Pennsylvania, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

27514

UNC at Chapel Hill Hospital, Chapel Hill

30322

Children's Healthcare of Atlanta, Atlanta

44106

University Hospital of Cleveland, Cleveland

53201

Comprehensive Center for Bleeding Disorders, Milwaukee

60612

Rush University Medical Center, Chicago

70112

Tulane University Health Sciences Center, New Orleans

73104

University of Oklahoma Health Sciences Center, Oklahoma City

75390

University of Texas Southwestern Medical Center, Dallas

76104

Cook Children's Medical Center, Fort Worth

92868

Children's Hospital of Orange County, Orange

02115

Children's Hospital Boston, Boston

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Genentech, Inc.

INDUSTRY

lead

Carelon Research

OTHER